Francesco Rodeghiero

Francesco Rodeghiero

Auto-generated profile, based on publicly available information

Francesco Rodeghiero

The Hematology Project Foundation Department of Cell Therapy and Hematology, San Bortolo Hospital Vicenza Italy

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2009 in Blood
Verified
Journal Article
Open access
PDF file
FRFrancesco Rodeghiero
Francesco Rodeghiero
RSRoberto Stasi
Roberto Stasi
TGTerry Gernsheimer
Terry Gernsheimer
MMMarc Michel
Marc Michel
DPDrew Provan
Drew Provan
JGJames N. George
James N. George
Diagnosis and management of immune thrombocytopenic purpura (ITP) remain largely dependent on clinical expertise and observations more than on evidence derived from clinical trials of high scientific quality. One major obstacle to the implementation of such studies and in producing reliable meta-analyses of existing data is a lack of consensus on standardized critical definitions, outcome criteria, and terminology. Moreover, the demand for comparative clinical trials has dramatically increased since the introduction of new classes of therapeutic agents, such as thrombopoietin receptor agonists, and innovative treatment modalities, such as anti-CD 20 antibodies. To overcome the present heterogeneity, an International Working Group of recognized expert clinicians convened a 2-day structured meeting (the Vicenza Consensus Conference) to define standard terminology and definitions for primary ITP and its different phases and criteria for the grading of severity, and clinically meaningful outcomes and response. These consensus criteria and definitions could be used by investigational clinical trials or cohort studies. Adoption of these recommendations would serve to improve communication among investigators, to enhance comparability among clinical trials, to facilitate meta-analyses and development of therapeutic guidelines, and to provide a standardized framework for regulatory agencies.

6 September 2010 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
FRF. Rodeghiero
F. Rodeghiero
ATA. Tosetto
A. Tosetto
TAT. Abshire
T. Abshire
DAD. M. Arnold
D. M. Arnold
BCB. Coller
B. Coller
OGON BEHALF OF THE ISTH/SSC JOINT VWF AND PERINATAL/PEDIATRIC HEMOSTASIS SUBCOMMITTEES WORKING GROUP
ON BEHALF OF THE ISTH/SSC JOINT VWF AND PERINATAL/PEDIATRIC HEMOSTASIS SUBCOMMITTEES WORKING GROUP

15 March 2006 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
ATA. Tosetto
A. Tosetto
FRF. Rodeghiero
F. Rodeghiero
GCG. Castaman
G. Castaman
AGA. Goodeve
A. Goodeve
AFA. B. Federici
A. B. Federici
IPI. Peake
I. Peake
Summary. Background: A quantitative description of bleeding symptoms in type 1 von Willebrand disease (VWD) has never been reported. Objectives: The aim was to quantitatively evaluate the severity of bleeding symptoms in type 1 VWD and its correlation with clinical and laboratory features. Patients and methods: Bleeding symptoms were retrospectively recorded in a European cohort of VWD type 1 families, and for each subject a quantitative bleeding score (BS) was obtained together with phenotypic tests. Results: A total of 712 subjects belonging to 144 families and 195 controls were available for analysis. The BS was higher in index cases than in affected family members (BS 9 vs. 5, P < 0.0001) and in unaffected family members than in controls (BS 0 vs. −1, P < 0.0001). There was no effect of ABO blood group. BS showed a strong significant inverse relation with either von Willebrand ristocetin cofactor (VWF:RCo), von Willebrand antigen (VWF:Ag) or factor VIII procoagulant activity (FVIII:C) measured at time of enrollment, even after adjustment for age, sex and blood group (P < 0.001 for all the four upper quintiles of BS vs. the first quintile, for either VWF:RCo, VWF:Ag or FVIII:C). Higher BS was related with increasing likelihood of VWD, and a mucocutaneous BS (computed from spontaneous, mucocutaneous symptoms) was strongly associated with bleeding after surgery or tooth extraction. Conclusions: Quantitative analysis of bleeding symptoms is potentially useful for a more accurate diagnosis of type 1 VWD and to develop guidelines for its optimal treatment.

24 November 2005 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
FRF. Rodeghiero
F. Rodeghiero
GCG. Castaman
G. Castaman
ATA. Tosetto
A. Tosetto
JBJ. Batlle
J. Batlle
FBF. Baudo
F. Baudo
ASA. Srivastava
A. Srivastava
Summary. Objective: The aim of this study was the validation of the criteria defining a significant mucocutaneous‐bleeding history in type 1 von Willebrand disease (VWD). Subjects and methods: To avoid selection bias, 42 obligatory carriers (OC) of type 1 VWD were identified from a panel of 42 families with type 1 VWD enrolled by 10 expert centers. OC were identified by the presence of an offspring and another first degree relative with type 1 VWD (affected subjects, AFF). A standardized questionnaire was administered to evaluate hemorrhagic symptoms at the time of first examination, using a bleeding score ranging from 0 (no symptom) to 3 (hospitalization, replacement therapy, blood transfusion). Sensitivity, specificity, diagnostic likelihood ratios, positive and negative predictive values for the diagnosis of type 1 VWD were calculated from the data collected in OC and in 215 controls. Results: Having at least three hemorrhagic symptoms or a bleeding score of 3 in males and 5 in females was very specific (98.6%) for the bleeding history of type 1 VWD, although less sensitive (69.1%). None of the misclassified OC had life‐threatening bleeding episodes after diagnosis. Conclusions: We suggest that the use of a standardized questionnaire and bleeding score may be useful for the identification of subjects requiring laboratory evaluation for VWD.

4 April 2013 in Blood
Verified
Journal Article
Closed access
PDF file
FRFrancesco Rodeghiero
Francesco Rodeghiero
MMMarc Michel
Marc Michel
TGTerry Gernsheimer
Terry Gernsheimer
MRMarco Ruggeri
Marco Ruggeri
VBVictor Blanchette
Victor Blanchette
RSRoberto Stasi
Roberto Stasi
In a previous publication on new terminology, definitions, and outcome criteria for immune thrombocytopenia (ITP), the International Working Group (IWG) on ITP acknowledged that response to treatment should consist of clinically meaningful end points such as bleeding manifestations and that platelet count may not be the ideal parameter for capturing the benefits of therapy. The IWG now proposes a consensus-based ITP-specific bleeding assessment tool (ITP-BAT) with definitions and terminology consistent with those adopted for other bleeding disorders. Bleeding manifestations were grouped into three major domains: skin (S), visible mucosae (M), and organs (O), with gradation of severity (SMOG). Each bleeding manifestation is assessed at the time of examination. Severity is graded from 0 to 3 or 4, with grade 5 for any fatal bleeding. Bleeding reported by the patient without medical documentation is graded 1. Within each domain, the same grade is assigned to bleeding manifestations of similar clinical impact. The “worst bleeding manifestation since the last visit” (observation period) is graded (a suitable database collection form is provided), and the highest grade within each domain is recorded. The SMOG system provides a consistent description of the bleeding phenotype in ITP, and the IWG unanimously supports its adoption and validation in future clinical studies.

13 July 2016 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
GAGiuseppe Astori
Giuseppe Astori
EAEliana Amati
Eliana Amati
FBFranco Bambi
Franco Bambi
MBMartina Bernardi
Martina Bernardi
KCKatia Chieregato
Katia Chieregato
FRFrancesco Rodeghiero
Francesco Rodeghiero
The use of fetal bovine serum (FBS) as a cell culture supplement is discouraged by regulatory authorities to limit the risk of zoonoses and xenogeneic immune reactions in the transplanted host. Additionally, FBS production came under scrutiny due to animal welfare concerns. Platelet derivatives have been proposed as FBS substitutes for the ex-vivo expansion of mesenchymal stem/stromal cells (MSCs) since platelet-derived growth factors can promote MSC ex-vivo expansion. Platelet-derived growth factors are present in platelet lysate (PL) obtained after repeated freezing–thawing cycles of the platelet-rich plasma or by applying physiological stimuli such as thrombin or CaCl2.PL-expanded MSCs have been used already in the clinic, taking advantage of their faster proliferation compared with FBS-expanded preparations. Should PL be applied to other biopharmaceutical products, its demand is likely to increase dramatically. The use of fresh platelet units for the production of PL raises concerns due to limited availability of platelet donors. Expired units might represent an alternative, but further data are needed to define safety, including pathogen reduction, and functionality of the obtained PL. In addition, relevant questions concerning the definition of PL release criteria, including concentration ranges of specific growth factors in PL batches for various clinical indications, also need to be addressed. We are still far from a common definition of PL and standardized PL manufacture due to our limited knowledge of the mechanisms that mediate PL-promoting cell growth. Here, we concisely discuss aspects of PL as MSC culture supplement as a preliminary step towards an agreed definition of the required characteristics of PL for the requirements of manufacturers and users.